2020 Fiscal Year Final Research Report

Approaching the darkness of oral Helicobacter pylori: exploratory research on isolation / identification, infection mechanism, and persistent infection regulators

Research Project

PDF

Project/Area Number	19K22704
Research Category	Grant-in-Aid for Challenging Research (Exploratory)
Allocation Type	Multi-year Fund
Review Section	Medium-sized Section 57:Oral science and related fields
Research Institution	Niigata University
Principal Investigator	Noiri Yuichiro 新潟大学, 医歯学系, 教授 (50218286)
Co-Investigator(Kenkyū-buntansha)	大墨竜也新潟大学, 医歯学系, 助教 (30759725) 竹中彰治新潟大学, 医歯学系, 准教授 (50313549) 三室仁美大阪大学, 微生物病研究所, 准教授 (80396887) 寺井崇二新潟大学, 医歯学系, 教授 (00332809) 横山純二新潟大学, 医歯学総合病院, 准教授 (70422615) 佐藤裕樹新潟大学, 医歯学系, 助教 (50644556)
Project Period (FY)	2019-06-28 – 2021-03-31
Keywords	ピロリ菌 / nested PCR / 胃がん / 口腔バイオフィルム / 感染機序
Outline of Final Research Achievements	The detection rate of Helicobacter pylori in the oral cavity is not clear.In this study,we attempted to detect H.pylori from oral biofilms using the Nested PCR methods.In this study,using a Nested PCR method was tried to detect H.pylori from oral biofilms.The Nested PCR method used in this study was able to detect H.pylori with high sensitivity. Subsequently,by Nested PCR method, from the gastric H.pylori suffering patient's gastric tissue,H.pylori DNA was detectable 100%.If H.pylori was alive in the oral cavity,the oral cavity could function as a persistent gastric infectious reservoir.Confirmation of the homology could not be carried out within the study period. Oral H.pylori DNA was frequently detected in patients with a history of gastric H.pylori infection.Oral H. pylori has characteristic distribution independent of sex and age,suggesting that it is part of the normal microflora in the oral cavity.
Free Research Field	歯科保存学
Academic Significance and Societal Importance of the Research Achievements	日本ヘリコバクターピロリ学会は，除菌で胃がんのリスクが34％程度（1/3）に低下するとの見解を示したが、除菌療法の成功率は，1次除菌，2次除菌併せて60-80％程度で頭打ち状態である。本研究の成果はこの日本の現状の打開策に留まらない。研究成果の波及を想定する規模としては，WHOが予測する2050年の世界の医療フィールドである。本研究構想は“胃がん予防戦略”と不適切な抗菌剤使用に伴う“耐性菌被害”（現在，クラリスロマイシン耐性ピロリ菌の出現が問題視），すなわち年間約1兆円の社会的・経済的損失と約1000万人の人命を救う挑戦の一翼を担う芽生え期の研究成果である。